SMTISanara MedTech Inc.
Price
+16%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, price roughly fair, growing in the filings, the market with it.
Charts
As reported to the SEC, without any scoring.
Sanara MedTech Inc. (SMTI) reported revenue of $28M in Q2 2026 (quarter ended Jun 30, 2026), up 9.0% from the same quarter a year earlier. That came with a gross margin of 93% and net loss of $453K. For the full year FY2025, revenue was $103M (+19% year on year) and net income −$38M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026Update on Regulatory Approvals As previously disclosed, MiMedx and Sanara filed their respective notification and report forms pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) on August 12, 2026.Shareholder vote results · Form 8-K
- Aug 11, 2026MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)Earnings release · press release
- Jul 29, 2026Agreement and Plan of Merger On July 29, 2026, Sanara MedTech Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, MiMedx Group, Inc., a Florida corporation (“Parent”) and Mustang Merger Sub, Inc., a Texas corporation and a wholly-owned subsidiary of …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #13 of 21 by RyuScore